ENIGMA: Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy

Sponsor
Martini Hospital Groningen (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05785299
Collaborator
(none)
120
2
26

Study Details

Study Description

Brief Summary

There are a lot of parents who believe that their child may not tolerate cow's milk because they develop symptoms such as redness of the skin or they may vomit. It is not always easy to find out if these infants should indeed avoid drinking cow's milk or that the symptoms are caused by something else, for instance because they have a viral illness. The goal of the investigators is to find out if cow's milk should be introduced in the hospital or if it can also be advised to perform the introduction at home to determine if an infant can drink cow's milk without developing symptoms. Half of the participants will drink cow's milk in the hospital. This test is performed on two days. On one of the days cow's milk will be offered. On the other day a look-alike substance is offered. The other half of the participants will drink cow's milk at home by starting to drink a little bit of milk and in a few steps drink a normal bottle of cow's milk. The main question is whether both tests can be used to find out if an infant can drink cow's milk without developing symptoms.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Cow's milk
  • Diagnostic Test: Placebo
  • Diagnostic Test: Home introduction
N/A

Detailed Description

Cow's milk allergy (CMA) is the most common food allergy among infants. CMA can be divided into immunoglobin E (IgE) and non-IgE-mediated allergy. In case of IgE-mediated allergy, symptoms occur within two hours after ingestion, and are potentially life-threatening. In patients without sensitisation, symptoms may occur up to 48 hours after ingestion and predominantly affect the gastrointestinal tract and skin. The gold standard to diagnose a cow's milk allergy is to perform a double-blind placebo controlled food challenge (DBPCFC). Determination of DBPCFC outcome for non-IgE-mediated allergy can be challenging due to delayed presentation of symptoms after the DBPCFC has been performed. Furthermore, in the majority of infants with non-IgE-mediated cow's milk allergy, symptoms are mild and therefore introduction under medical supervision is superfluous. To date, there is no validated diagnostic to confirm a diagnosis of non-IgE-mediated cow's milk allergy and potential over diagnosis is due to the overlap of symptoms with other common diseases in infants.

The aim of this study is to compare the outcome of an adjusted DBPCFC and introduction at home of cow's milk for children with a suspected non-IgE-mediated cow's milk allergy

Patients with a suspected cow's milk allergy will be randomized to a DBPCFC or home introduction of cow's milk after sensitisation for cow's milk has been excluded and parents have not reported severe symptoms during introduction of cow's milk. Outcome of both introduction methods will be based on predefined criteria. For patients with a negative outcome of the test unrestricted exposure to cow's milk is recommended. In case of a positive outcome, parents are recommended to gradually increase the amount of cow's milk in their child's diet by means of the "milk ladder". During regular follow-up visits the investigators will inquire whether introduction of cow's milk is successful and if needed motivate parents to continue further introduction. Number of all consultations will be registered.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Evaluation of the Outcome of Clinical or Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy (ENIGMA Trial)
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
Dec 1, 2024
Anticipated Study Completion Date :
Jun 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Double blind placebo controlled challenge test

Introduction of cow's milk by means of an adjusted double blind placebo controlled challenge test

Diagnostic Test: Cow's milk
clinical introduction of cow's milk
Other Names:
  • Oral food challenge test
  • Diagnostic Test: Placebo
    clinical introduction of placebo
    Other Names:
  • Oral food challenge test
  • Active Comparator: Home introduction test

    Introduction of cow's milk by means of a standardized schedule

    Diagnostic Test: Home introduction
    home introduction of cow's milk

    Outcome Measures

    Primary Outcome Measures

    1. Number of participants with a positive or negative test [Determined 1 week after start of the test]

      Positive (intolerant) or negative (tolerant) outcome of the introduction test

    Secondary Outcome Measures

    1. Regular milk consumption [Determined 6 weeks after completion of the test]

      Milk consumption is based on normal daily intake for age

    2. Percentage and type of reported symptoms [Determined 6 weeks after completion of the test]

      Reported symptoms are classified according to predefined criteria

    3. Healthcare utilisation during the study period [Determined 6 weeks after completion of the test]

      Healthcare utilisation is determined by evaluation of the number of physical and telephone consultations

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Month to 18 Months
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • maximum age of eighteen months;

    • suspected to be allergic for cow's milk (based on medical history);

    Exclusion Criteria:
    • children older than the age of eighteen months;

    • sensitised for cow's milk (i.e. SPT >3mm (in combination with positive control ≥3mm) or specific IgE >0.35 kU/L)

    • patient suffers from acute (i.e. within one hour after cow's milk had been eaten) and moderate-severe IgE-mediated symptoms after ingestion of cow's milk

    • patient suffers from symptoms according to the FPIES criteria after ingestion of cow's milk

    • patient uses beta blockers and/or prednisolone;

    • patient suffers from uncontrolled respiratory symptoms or severe eczema or a chronic condition because of which the patients cannot be included as judged by the treating physician;

    • parents are unable to adequately report the occurrence of possible symptoms (e.g. insufficient language proficiency).

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Martini Hospital Groningen

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Arvid Kamps, Principal investigator, Martini Hospital Groningen
    ClinicalTrials.gov Identifier:
    NCT05785299
    Other Study ID Numbers:
    • ABR 83741
    First Posted:
    Mar 27, 2023
    Last Update Posted:
    Mar 27, 2023
    Last Verified:
    Mar 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 27, 2023